To determine whether Gas6 is preferentially expressed in a particular breast cancer subtype, we categorized patient samples from the TMAs as luminal A, luminal B, Her2+ and TNBC, based on clinical attributes including hormone receptor status, Her2 status, and Ki67 expression. This evidence concerns the gene NR4A1 and breast carcinoma.